Marker Therapeutics, Inc. (MRKR) Key Metrics
MRKR valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $17.3M
- Enterprise value
- $9.3M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 4.9 10-yr median 14.6
- Price / book
- 1.7 10-yr median 2.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.53
MRKR key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMRKR valuation Price multiples at each fiscal year-end price.
Price / sales+51.8%
6.4
2025 · hover or tap a bar for each year
20162025
Price / book−9.8%
1.4
2025 · hover or tap a bar for each year
20162025
Free cash flow yield−13.6 pts
−52.7%
2025 · hover or tap a bar for each year
20162025
MRKR returns How much profit the business earns on the capital it uses.
Return on equity−3.0 pts
−68.8%
2025 · hover or tap a bar for each year
20162025
Return on assets−4.4 pts
−59.2%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin−173.2 pts
−338.7%
2025 · hover or tap a bar for each year
20162025
Asset turnover−48.7%
0.17
2025 · hover or tap a bar for each year
20162025
MRKR per-share figures Results divided by the shares outstanding at year-end.
Revenue per share−68.4%
$0.23
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.79
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$0.78
2025 · hover or tap a bar for each year
20162025
Book value per share−46.9%
$1.10
2025 · hover or tap a bar for each year
20162025
Shares outstanding+70.5%
15.3M
2025 · hover or tap a bar for each year
20162025
MRKR financial health Debt, liquidity and how easily interest is covered.
Net debt+$3.1M
−$16.1M
2025 · hover or tap a bar for each year
20162025
Current ratio+31.9%
8.39
2025 · hover or tap a bar for each year
20162025
MRKR efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+98 days
191 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue0.0 pts
0.0%
2025 · hover or tap a bar for each year
20162025
MRKR valuation history
Fiscal year-endToday10-year median
MRKR returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MRKR debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MRKR cash returned to shareholders
DividendsBuybacksFree cash flow
MRKR price vs earnings per share
Share price at year-endEPS (right axis)
MRKR key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $22.8M | $27.9M | $48.4M | $22.5M | $72.7M | $68.2M | $131.3M | — | — | $287.9M |
| Enterprise value | $6.7M | $8.7M | $33.3M | $18.4M | $42.2M | $59.1M | $87.9M | — | — | $280.1M |
| Price / sales | 6.4 | 4.2 | 14.6 | 6.4 | 58.5 | 146.1 | 615.9 | — | — | — |
| Price / book | 1.4 | 1.5 | 3.4 | 1.2 | 1.7 | 2.5 | 3.0 | — | — | 46.6 |
| EV / sales | 1.9 | 1.3 | 10.1 | 5.2 | 34.0 | 126.6 | 412.2 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 46.4 |
| Earnings yield | −53.3% | −38.4% | −17.0% | −132.7% | −57.6% | −42.1% | −16.3% | — | — | −0.9% |
| Free cash flow yield | −52.7% | −39.1% | −33.9% | −119.6% | −41.8% | −42.9% | −14.2% | — | — | −2.3% |
| Shareholder yield (dividends + buybacks) | — | — | — | — | — | 0.0% | 0.0% | — | — | 0.0% |
| Share price at fiscal year-end | $1.49 | $3.11 | $5.50 | $2.70 | $9.50 | $14.50 | $28.80 | $55.50 | $39.20 | $38.80 |
| Per share | ||||||||||
| Revenue per share | $0.23 | $0.73 | $0.38 | $0.42 | $0.16 | $0.10 | $0.05 | — | — | $0.00 |
| Earnings per share | −$0.79 | −$1.20 | −$0.94 | −$3.58 | −$5.47 | −$6.10 | −$4.70 | — | — | −$0.33 |
| Operating cash flow per share | −$0.78 | −$1.21 | −$1.87 | −$3.23 | −$3.57 | −$4.26 | −$4.01 | — | — | −$0.88 |
| Free cash flow per share | −$0.78 | −$1.21 | −$1.87 | −$3.23 | −$3.97 | −$6.23 | −$4.09 | — | — | −$0.88 |
| Cash per share | $1.05 | $2.14 | $1.72 | $1.41 | $5.54 | $4.54 | $9.63 | — | — | $1.06 |
| Book value per share | $1.10 | $2.07 | $1.60 | $2.35 | $5.75 | $5.81 | $9.67 | — | — | $0.83 |
| Tangible book value per share | $1.10 | $2.07 | $1.60 | $2.35 | $5.75 | $5.81 | $9.67 | — | — | $0.83 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.41 | $1.97 | $0.08 | — | — | $0.02 |
| Debt per share | — | — | — | $0.91 | $1.55 | $2.61 | $0.11 | — | — | $0.00 |
| Shares outstanding | 15.3M | 9.0M | 8.8M | 8.4M | 7.7M | 4.7M | 4.6M | — | — | 7.4M |
| Change in shares outstanding | +70.5% | +1.9% | +5.5% | +9.1% | +62.6% | +3.2% | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −68.8% | −65.8% | −49.0% | −94.1% | −117.4% | −80.4% | −41.4% | −469.7% | −223.1% | — |
| Return on invested capital (ROIC) | — | — | — | −108.1% | −196.4% | −241.3% | — | — | — | — |
| Return on assets (ROA) | −59.2% | −54.8% | −32.0% | −58.4% | −73.6% | −62.4% | −39.5% | −439.5% | −167.6% | −33.7% |
| Return on tangible assets | −63.8% | −48.7% | −48.1% | −87.0% | −61.5% | −62.9% | −46.2% | −238.1% | −212.0% | −31.0% |
| Free cash flow margin | −338.7% | −165.5% | −496.5% | −767.7% | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | — | — | — | $7.6M | $11.9M | $12.3M | $484,379 | $49,000 | $5,000 | $5,000 |
| Cash & short-term investments | $16.1M | $19.2M | $15.1M | $11.8M | $42.4M | $21.4M | $43.9M | $61.7M | $5.1M | $7.9M |
| Net debt | −$16.1M | −$19.2M | −$15.1M | −$4.2M | −$30.5M | −$9.1M | −$43.4M | −$61.7M | −$5.1M | −$7.8M |
| Debt / equity | — | — | — | 0.39 | 0.27 | 0.45 | 0.01 | 0.00 | 0.00 | 0.00 |
| Debt / assets | — | — | — | 0.22 | 0.17 | 0.27 | 0.01 | 0.00 | 0.00 | 0.00 |
| Net debt / EBITDA | — | — | — | — | — | — | — | −300.04 | −28.00 | −1.30 |
| Current ratio | 8.39 | 6.36 | 5.57 | 2.14 | 3.56 | 3.81 | 22.83 | 22.11 | 3.40 | 4.56 |
| Quick ratio | 8.39 | 6.36 | 5.89 | 2.14 | 3.56 | 3.97 | 22.83 | 22.11 | 3.40 | 4.56 |
| Interest coverage | — | — | — | — | — | -194.2 | — | — | — | — |
| Working capital | $16.8M | $18.6M | $14.1M | $8.8M | $33.1M | $18.0M | $43.5M | $59.2M | $3.7M | $6.2M |
| Invested capital | $728,766 | −$634,034 | −$1.1M | $15.4M | $13.5M | $18.2M | $666,653 | −$2.4M | −$1.5M | −$1.7M |
| Tangible asset value | $16.8M | $18.6M | $14.1M | $19.6M | $44.0M | $27.3M | $44.1M | $59.3M | $3.7M | $6.2M |
| Net current asset value | $16.8M | $18.6M | $14.1M | $1.8M | $21.8M | $6.1M | $43.2M | $59.2M | $3.7M | $6.2M |
| Graham net-net per share | $0.97 | $1.95 | $1.40 | −$0.15 | $2.38 | $0.71 | $9.14 | — | — | $0.82 |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | $0 | $0 | $71,710 | $310,493 | $0 |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 252.2% | 1,982.3% | 175.9% | 71.7% | 80.7% | — |
| Capex / depreciation | — | 2.00 | 0.00 | 0.00 | 0.99 | 8.60 | 1.31 | 0.00 | 0.01 | 0.02 |
| Stock-based compensation / revenue | 15.2% | 3.7% | 25.9% | 94.1% | 480.3% | 1,120.1% | 2,512.7% | 7,937.4% | 1,495.8% | — |
| R&D / revenue | 332.7% | 204.3% | 314.6% | 340.6% | 2,238.4% | 4,044.9% | 5,987.4% | 60,195.0% | 2,868.4% | — |
| SG&A / revenue | 118.0% | 64.4% | 225.8% | 322.6% | 1,040.9% | 2,243.4% | 4,679.9% | 11,835.3% | 3,502.6% | — |
| Efficiency | ||||||||||
| Days sales outstanding | 191.2 | 93.4 | 189.0 | 124.8 | 147.1 | 413.2 | 140.7 | 191.7 | — | — |
| Days of inventory on hand | — | — | -34.6 | — | — | -19.3 | — | — | — | — |
| Days payables outstanding | — | 27.5 | 36.1 | 95.2 | 466.2 | 38.0 | 37.3 | 3.9 | 58.9 | — |
| Cash conversion cycle (days) | — | 66.0 | 118.3 | 29.6 | -319.1 | 355.9 | 103.4 | 187.8 | — | — |
| Receivables turnover | 1.91 | 3.91 | 1.93 | 2.93 | 2.48 | 0.88 | 2.59 | 1.90 | — | — |
| Payables turnover | — | 13.29 | 10.10 | 3.83 | 0.78 | 9.61 | 9.77 | 94.15 | 6.20 | 0.00 |
| Asset turnover | 0.17 | 0.34 | 0.13 | 0.07 | 0.02 | 0.01 | 0.00 | 0.01 | 0.03 | 0.00 |
| Average receivables | $1.9M | $1.7M | $1.7M | $1.2M | $500,398 | $528,374 | $82,183 | $108,177 | — | — |
| Average payables | $929,864 | $1.0M | $1.0M | $3.1M | $4.0M | $2.0M | $1.3M | $1.3M | $847,500 | $685,547 |
| Average inventory | — | — | −$988,126 | — | — | −$1.0M | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MRKR's annual financial statements (latest annual report filed March 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MRKR valuation and financial ratios
Marker Therapeutics earned a return on equity of −68.8% in fiscal 2025. The share count rose 106.3% from 7.4M to 15.3M over 9 years.
See the MRKR income statement, the MRKR chart for price history, or the MRKR stock overview for the latest quote and news.
MRKR key metrics FAQ
What is Marker Therapeutics's return on equity?
Marker Therapeutics's return on equity (ROE) was −68.8% in fiscal 2025: net income of -$12.2 million on average shareholders' equity of $17.7 million.
What is Marker Therapeutics's free cash flow yield?
Marker Therapeutics generated -$12.0 million of free cash flow in fiscal 2025, a free cash flow yield of −52.7% on its market value at year-end ($22.8 million).
What is Marker Therapeutics's current ratio?
Marker Therapeutics's current ratio was 8.39 at the end of fiscal 2025: current assets were 8.39 times current liabilities.